Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Laxative Ingredient Pediatric Study Provides Compass For FDA Action

This article was originally published in The Tan Sheet

Executive Summary

FDA supports research to evaluate long-term exposure of polyethylene glycol 3350 in children, saying “pharmacokinetic data from pediatric patients would provide better information” on the ingredient’s safety. A consumer group that petitioned FDA for a black box warning has additional questions.

You may also be interested in...

MiraLAX Targeted In Petition To FDA, But Physicians Back Pediatric Use

A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

FTC Commissioner Proposes Making Endorsement Guides Into Rules, Seeking Stiffer Penalties

At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts